Mengniu promotes LC19 probiotic strain to stimulate GLP-1 secretion

As GLP-1 weight management benefits gain rapid traction, China dairy giant Mengniu is preparing for a functional food era by promoting its patented probiotic strain LC19 for natural metabolic regulation.

Key Clinical Takeaways:
• Mengniu has launched an entire documentary highlighting its LC19 probiotic strain and its role in stimulating GLP-1 hormone secretion.
• Research published in the international scientific journal Cell demonstrates that LC19 synthesizes Tryptophan-cholic acid (Trp-CA) using tryptophan and bile acids.
• The dairy giant plans to move the strain beyond probiotic supplements and into everyday functional items like senior milk powders, adult milk powders, and chilled fermented dairy.

Probiotic LC19 Targets Natural GLP-1 Secretion Pathways

While GLP-1 drugs remain centered on diabetes management across the Asia Pacific region, awareness of broader weight control benefits is surging due to widespread utilization in the United States. Food and beverage manufacturers in China and India, where generic GLP-1 drugs are produced, are positioning themselves for an eventual shift toward companion food and drink products. Mengniu is spearheading this transition by spotlighting its LC19 probiotic strain through a dedicated promotional documentary.

The scientific mechanism behind the strain involves active metabolites that influence hormone release. According to Peking University Professor Pang Yanli, who collaborated with Mengniu on the research, a major active metabolite driving GLP-1 hormone secretion is Tryptophan-cholic acid (Trp-CA). This metabolite regulates glucose metabolism and body weight. Individuals experiencing poor blood glucose control typically exhibit reduced levels of Trp-CA, which functions through a newly identified pathway for metabolic regulation. Researchers targeted this exact pathway to isolate bacterial strains capable of efficiently producing Trp-CA.

Validation in Cell and Expansion into Chilled Dairy

The selection of the LC19 strain hinges on its unique capacity to synthesize Trp-CA in the human body using dietary amino acid tryptophan alongside bile acids, subsequently engaging the targeted metabolic pathway. The research validating this process has been peer-reviewed and published in the international scientific journal Cell. Building on these findings, Mengniu has already introduced commercial probiotic supplements containing the strain, such as the YouRuiAn Sugar Shield probiotic powder.

Company leadership intends to scale the ingredient into broader daily diet categories. Mengniu Product R&D Centre General Manager Shusen Li stated that the prebiotics assist individuals showing pre-diabetic symptoms and early blood glucose abnormalities without pharmacological intervention. The firm has identified chilled dairy as a primary growth driver amid broader market pressures, pointing to improving cold-chain infrastructure and supply chain capabilities. Company estimates project that chilled fermented dairy products, such as yogurt, register about 2.4 daily consumer touchpoints across breakfast, afternoon tea, and meal replacement scenarios, offering a frequent delivery mechanism for glucose metabolism benefits.

With an intellectual property portfolio exceeding 18,000 probiotic strains, Mengniu maintains that LC19 represents just the initial phase of its offerings aimed at capitalising on regional interest in GLP-1 mechanisms, blood sugar regulation, and metabolic health.

Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.